ANIP - Company ID 0001023024
The table below shows ANI PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $237.46M | $227.81M | $211.37M | $197.12M | $148.33M | $138.04M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $10.60M | $12.30M | $16.54M | $10.56M | $10.13M | $7.30M |
ANI PHARMACEUTICALS INC reported annual revenue of $883.37M for fiscal year 2025. That is up 43.8% from $614.38M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $128.62M (FY 2016) to $883.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $73.66M |
| $76.66M |
| $81.77M |
| $76.53M |
| $79.08M |
| $52.82M |
| Operating income | $38.89M | $36.24M | $13.89M | $26.19M | -$20.52M | $5.17M |
| Income tax | $10.73M | $7.18M | $1.98M | $4.31M | -$7.33M | $0.00 |
| Net income | $29.49M | $26.62M | $8.55M | $15.68M | -$24.17M | -$2.29M |
| EPS (diluted) | $1.28 | $1.13 | $0.36 | $0.69 | -$1.27 | -$0.14 |